Company Overview of Aridis Pharmaceuticals Inc.
Aridis Pharmaceuticals Inc., a biopharmaceutical company, develops anti-infective product candidates. The company offers AR-301, an anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AR-101 and AR-104 that are specific lgM monoclonal antibodies, which target pseudomonas aeruginosa; and Aerucin, a broadly reactive monoclonal antibody against Pseudomonas aeruginosa. It also provides Panaecin, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR201, a human monoclonal antibody, which treats respiratory syncytial virus infections; and AR401, a human monoclonal antibody for the treatment of Nosocomial ...
5941 Optical Court
San Jose, CA 95138
Founded in 2005
Key Executives for Aridis Pharmaceuticals Inc.
Founder, Chief Executive Officer, and Director
Chairman of the Board and President
Compensation as of Fiscal Year 2016.
Aridis Pharmaceuticals Inc. Key Developments
Aridis Pharmaceuticals Inc. Announces Appointments to Clinical Advisory Board
Jul 11 16
Aridis Pharmaceuticals Inc. announced the addition of three highly recognized experts, Bruno Francois, M.D., Jean Chastre, M.D., and Marin Kollef, M.D., F.A.C.P., F.C.C.P., to the company's Clinical Advisory Board. These world-renowned authorities in hospital-acquired and ventilator-associated pneumonia (HAP and VAP) and infectious disease in the intensive care medicine (ICU) setting are bringing their experience and knowledge to help drive Aridis' leading edge clinical programs forward. Dr. Francois, a specialist in intensive care medicine and anesthesiology, heads the Limoges Clinical Investigation Center with a specific focus on infectious diseases in critically ill patients at the University Hospital of Limoges, France. Dr. Chastre, Consulting Professor in the Medical ICU and former director of the same ICU at Institut de Cardiologie, Groupe Hospitalier Piti -Salptri re in Paris, France, also served as a member of the Clinical Advisory Board at Kenta Biotech AG. Dr. Kollef is the director of the medical intensive care unit and respiratory care services at Barnes-Jewish Hospital in St. Louis, Missouri.
Aridis Pharmaceuticals Appoints Robert Ruffolo to its Board of Directors
Apr 18 16
Aridis Pharmaceuticals Inc. announced that it has appointed a pharmaceutical executive Robert Ruffolo, Jr., Ph.D., D.Sc.(h), D.Eng.(h), F.C.P.P., to its Board of Directors. Dr. Ruffolo is the retired President of Research and Development at Wyeth Pharmaceuticals (now Pfizer), and retired Corporate Senior Vice President of Wyeth. He has also held senior leadership roles at SmithKline Beecham (now GlaxoSmithKline) and Lilly Research Laboratories. Dr. Ruffolo brings substantial drug discovery and development expertise to Aridis. At Wyeth, Dr. Ruffolo managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion. Prior to Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) where he was Senior Vice President and Director of Biological Sciences, Worldwide.
Aridis Pharmaceuticals Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 08:45 AM
Jan 18 16
Aridis Pharmaceuticals Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 08:45 AM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States. Speakers: Vu L. Truong, Founder, Chief Executive Officer, and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 12, 2016
November 4, 2015